作者: Park, Hyo-Jin ; Lee, Do-Geon ; Kim, Eun-Young ; Oh, Seung-Hwan ; Park, Se-Pill ; Pyeon, Da-Bin ; Kim, So-Hee ; Yoon, Jae-Wook ; Lee, Seung-Eun ; Park, Chan-Oh

Summary:

Our previous studies have already revealed that β-cryptoxanthin (BCX), hesperetin (HES), and icariin (ICA) antioxidants are effective for in vitro maturation (IVM) of porcine oocytes. In this study, we investigated which of BCX, HES, or ICA was more effective for IVM of porcine oocytes. The antioxidant properties were assessed with aged porcine oocytes and embryos by comparing 2,2-diphenyl-1-(2,4,6-trinitrophenyl)hydrazyl (DPPH), reducing power, and H2O2 scavenging activity assays. The chemical assay results demonstrated that BCX had a greater DPPH scavenging activity and reducing power than HES and ICA, compared with controls. However, the H2O2 scavenging activity of the antioxidants was similar when tested at the optimal concentrations of 1 μM BCX (BCX-1), 100 μM HES (HES-100), and 5 μM ICA (ICA-5). The biological assay results showed that BCX-1 treatment was more effective in inducing a significant reduction in reactive oxygen species (ROS), improving glutathione levels, and increasing the expression of antioxidant genes. In addition, BCX-1 inhibited apoptosis by increasing the expression of anti-apoptotic genes and decreasing pro-apoptotic genes in porcine parthenogenetic blastocysts. BCX-1 also significantly increased the blastocyst formation rate compared with the ageing control group, HES-100 and ICA-5. This study demonstrates that damage from ROS produced during oocyte ageing can be prevented by supplementing antioxidants into the IVM medium, and BCX may be a potential candidate to improve assisted reproductive technologies.

2020-06-12·Journal of biomaterials science. Polymer edition3区 · 工程技术

A microfluidic system based on the monoclonal antibody BCMab1 specifically captures circulating tumor cells from bladder cancer patients

3区 · 工程技术

Article

作者: Men, Tongyi ; Wang, Yunchao ; Liu, Qing ; Liang, Ye ; Wang, Jianning ; Niu, Haitao

Circulating bladder tumor cells provide significant information for cancer diagnosis, tumor staging and personalized cancer therapy. Previous studies have reported various methods for capturing circulating tumor cells; however, capturing circulating tumor cells remain a challenge. Here, we present a microfluidic chip with high specificity and capture yields that we refer to as a bladder cancer diagnosis chip. We show that this chip can be used to effectively capture circulating bladder cancer cells based on antibody-BCMab1, a monoclonal antibody that binds to aberrantly glycosylated integrin a3b1. This capture platform is composed of a polydimethylsiloxane (PDMS) chip, whose microchannels are functionalized with biotinylated BCMab1. To change the direction of flow to increase cell-substrate contact, we also introduced a herringbone or chevron channel pattern into the chip. Using this system, we were able to capture bladder cancer cells with high specificity. The capture rates of the bladder cancer diagnosis chip were evaluated at different flow rates and cell concentrations. We found that 90% of the cancer cells were successfully captured at flow rates of 10 μL/min and at various cell concentrations. This highly specific microfluidic chip is a novel tool for bladder cancer diagnosis and offers an opportunity for personalized treatment.

2017-07-11·Oncotarget

BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor

Article

作者: Yan, Ruping ; Chen, Haige ; Li, Chong ; Wang, Jiansong ; Wang, Haifeng ; Zhang, Ruiyun ; Yang, Zhao

Bladder cancer is one of the most common malignancies. However, there is no ideal therapy to cure bladder cancer so far, especially invasive carcinoma. Here, we developed a new antibody-based drug BCMab1-Ra, which was generated by conjugation of BCMab1 (a new monoclonal antibody that specifically recognized the aberrantly glycosylated Integrin a3b1 in bladder cancer) with the ricin A chain (Ra). A patient with multiple bladder cancer received intravescical administration of BCMab1-Ra treatment as a volunteer. After 30 weeks of treatment, no tumor was observed by cystoscope examination. We did not observe any local or systemic side effects. Human anti-mouse antibody (HAMA) was not detectable in the circulation. Results follow-up showed no tumor had been found in every half year review in 3 years.

项与 BCMab-1 相关的新闻（医药）

2023-08-14

·PRNewswire

Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights

Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression Pelareorep selected for inclusion in the Precision PromiseSM phase 3 platform trial in pancreatic cancer, designed to accelerate registration path and reduce by ~50% phase 3 costs compared to traditional trial $24.4 million in cash, cash equivalents and marketable securities as of June 30, 2023 provides projected runway into H2 2024 Strengthened financial position with a successful US$15 million public offering on August 8, 2023 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 14, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted. "Our core programs in pancreatic and breast cancer are both progressing rapidly towards registrational studies on the back of the impressive clinical data showing the potential of pelareorep as a backbone immunotherapy," said Dr. Matt Coffey, President and Chief Executive Officer. "Data reported at the American Society of Clinical Oncology (ASCO) Annual Meeting from our BRACELET-1 randomized phase 2 trial demonstrated robust improvements in objective response rate (ORR) and progression-free survival (PFS) with a hazard ratio of 0.29 (95% CI: 0.09, 0.98). This has unlocked the potential for including PFS as a dual endpoint in our registrational trial, which could considerably reduce the time to a pivotal readout. At the same time, pelareorep was selected for inclusion in the ongoing Precision Promise pancreatic cancer platform trial. Precision Promise, created by the Pancreatic Cancer Action Network, provides us with the opportunity to reduce the time and costs needed for a potential approval, and we are honored to have been selected for participation in this novel and exclusive trial." Second Quarter and Subsequent Highlights Breast Cancer Program BRACELET-1 data demonstrated a >50% improvement in progression-free survival and a nearly three-fold increase in confirmed overall response rate An oral presentation at the ASCO Annual Meeting featured results from a randomized trial of pelareorep in HR+/HER2- metastatic breast cancer. As of a March 3, 2023 cut-off date, BRACELET-1 data in the paclitaxel plus pelareorep cohort showed median PFS of 9.5 months, compared to 6.3 months in the paclitaxel monotherapy cohort. This resulted in a hazard ratio of 0.29 (95% CI: 0.09, 0.98), indicating the pelareorep-paclitaxel combination reduced the risk of disease progression by 71%. Confirmed ORR in these cohorts was 37.5% for paclitaxel plus pelareorep and 13.3% for paclitaxel. Overall survival data continues to mature as several patients are still on study. With these data, the HR+/HER2- metastatic breast cancer program is now phase 3-ready, and, with two randomized phase 2 trials showing meaningful benefits to patients, the focus is now on progressing to a registrational trial evaluating pelareorep-paclitaxel compared to paclitaxel alone. Oncolytics hosted a key opinion leader (KOL) webinar on June 5, 2023 where breast cancer experts and the management team discussed recent data from the BRACELET-1 study. A link to the replay is available by clicking here. Pancreatic Cancer Program Pelareorep selected for inclusion in Precision Promise Pivotal Phase 3 Platform Trial Pelareorep has been selected for inclusion as a new investigational treatment in Precision Promise. Created by the Pancreatic Cancer Action Network (PanCAN), Precision Promise is an innovative adaptive phase 3 clinical trial designed to streamline registration pathways for promising pancreatic cancer therapies. Inclusion is expected to accelerate the registrational pathway and reduce by half the phase 3 costs compared to a traditional trial. The study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel in comparison to gemcitabine and nab-paclitaxel standard of care therapy. This clinical study is expected to support the approval of the pelareorep combination therapy as a treatment for first-line metastatic pancreatic ductal adenocarcinoma. Additional Immunotherapeutic Opportunity Preclinical pelareorep-chimeric antigen receptor (CAR) T cell therapy combination program A poster presentation at ASCO showed preclinical results of pelareorep synergistically enhancing CAR T cell therapy efficacy in murine solid tumor models (link to the poster). The results suggest pelareorep could substantially expand the commercial potential of CAR T cell therapy beyond hematologic malignancies to include solid tumors, which represent the vast majority of cancer cases. Oncolytics is currently advancing preclinical research collaborations evaluating pelareorep-CAR T cell combination therapies. Financial Highlights As of June 30, 2023, the Company reported $24.4 million in cash, cash equivalents, and marketable securities, then successfully closed a US$15 million public offering on August 8, 2023. On a pro forma basis, including the estimated US$13.6 million in net proceeds from the public offering, the Company's cash, cash equivalents and marketable securities would have been approximately $42.7 million. The net loss for the second quarter of 2023 was $7.4 million, compared to a net loss of $5.1 million for the second quarter of 2022. The basic and diluted loss per share was $0.12 in the second quarter of 2023, compared to a basic and diluted loss per share of $0.09 in the second quarter of 2022. Net cash used in operating activities for the six months ended June 30, 2023 was $16.3 million, compared to $13.2 million for the six months ended June 30, 2022. The change reflected higher net operating activities and non-cash working capital changes. General and administrative expenses for the second quarter of 2023 were $3.5 million, compared to $2.8 million for the second quarter of 2022. The increase was primarily due to higher investor relations activities and annual general meeting of shareholders costs. Research and development expenses for the second quarter of 2023 were $3.7 million, compared to $3.2 million for the second quarter of 2022. The increase was primarily due to higher manufacturing expenses associated with an engineering production run along with process and analytical development activities and higher personnel-related expenses. The increase was partly offset by lower BRACELET-1 study costs. Anticipated Milestones and Catalysts Updated GOBLET study data in advanced/metastatic pancreatic ductal adenocarcinoma (PDAC): H2 2023 Update on GOBLET study's metastatic colorectal and anal cancer cohorts: H2 2023 Guidance on both the HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC registration paths: H2 2023 BRACELET-1 phase 2 metastatic breast cancer study overall survival data Webcast and Conference Call Management will host a conference call for analysts and investors at 8:30 a.m. ET today, August 14, 2023. To access the call, please dial (888) 664-6383 (North America) or (416) 764-8650 (International) and, if needed, provide confirmation number 5411-4798. To join the conference call without operator assistance, please click here. A live webcast of the call will also be available by clicking here or on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 114-798#. ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (unaudited) (in thousands of Canadian dollars, except share amounts) ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (unaudited) (in thousands of Canadian dollars) ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (in thousands of Canadian dollars) About the Pancreatic Cancer Action Network The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official "Give with Confidence" charity, indicating strong financial health, ongoing accountability and transparency. About Oncolytics Biotech Inc. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: . This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; our belief that our core programs in pancreatic and breast cancer are both progressing rapidly towards registrational studies; our belief that recent data has unlocked the potential for including PFS as a dual endpoint in our registrational trial, which could considerably reduce the time to a pivotal readout; our plans and expectations regarding the inclusion of pelareorep in the Precision Promise pancreatic cancer platform trial; our anticipated milestones and catalysts; our plans to advance towards a registrational study in metastatic breast cancer and pancreatic cancer; our belief that our combined cash resources provide a runway into H2 2024; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Logo: SOURCE Oncolytics Biotech® Inc.

临床结果临床3期免疫疗法ASCO会议临床2期

2023-01-30

·生物谷

《循环》：运动太猛或许不利于心血管！科学家发现，剧烈和非常剧烈的运动与冠状动脉钙化增加有关

总的来说，运动强度与冠状动脉粥样硬化的进展有关，其中剧烈运动与较少的CAC进展有关，而非常剧烈运动与更多的CAC和斑块进展有关，这可能主要是由于钙化斑块增加。运动可以说是成本最低最不受各种客观因素限制的改善健康的方法，尤其是在心血管疾病方面。在最活跃的人群中，心血管疾病平均风险可降低30-40%[1,2]，但近年来有一些出人意料的研究结果显示，业余运动员相比不那么活跃的健康对照组，冠状动脉粥样硬化程度增加[3-6]，他们的冠状动脉钙化（CAC）评分通常≥100阿加斯顿单位，且与运动量和和运动训练强度有关[4]。不过，先前的这些研究是横断面研究，无法确定运动是否加速冠状动脉粥样硬化、影响斑块形态。为此，荷兰内梅亨大学医学中心的研究人员开展了一项研究，他们发现，只有运动强度与CAC的进展有关，尤其是非常剧烈的运动，与CAC评分增加较多有关，剧烈运动与CAC评分增加较少有关，非常剧烈的运动还和钙化斑块进展风险增加有关。这项研究发表在Circulation杂志上[7]。本研究基于MARC-2（运动员心血管事件风险测量-2）研究，MARC-2是对MARC-1研究的随访，MARC-1研究在2012-2014年间，利用CT成像对318名健康的中年及以上（≥45岁）男业余运动员的亚临床冠状动脉粥样硬化进行了评估，幸存的314人被邀请参与MARC-2研究，最终291人接受邀请，平均随访时间为6.3±0.5年。本次分析排除了2名在参与MARC-2研究前接受冠状动脉支架治疗的参与者，因为介入治疗会导致他们的CAC和斑块特征评估不准确。最终，287人纳入了CAC分析，284人纳入了斑块分析。研究人员使用问卷对参与者的运动类型、每项运动的持续时间（年）、平时训练的频率和持续时间，以及表现水平（娱乐或竞技）进行了收集，并为每种运动分配一个代谢当量（MET）以表征运动强度，同时考虑参与者报告的表现水平，为同种运动不同水平分配不同的MET，例如网球分两档为5/7.3，游泳为8/10。奇点糕再举几个例子给大家参考一下，瑜伽为2.5，跑步分4档为6/7/9.3/11.8，足球为7，羽毛球为5.5，普通城市骑行为6.8，竞速骑行为7.5，山地骑行为8.5。运动强度划分为4档，＜3 METs为轻度，3-6 METs为中等，6-9 METs为剧烈，≥9 METs为非常剧烈。由于只有9人报告了轻度运动且轻度运动在总运动量中占的比例很少，因此分析排除了轻度这一档。入组MARC-1后，参与者的运动量为41（25-57）MET小时/周，其中，中等强度运动占比0%（0-19%），剧烈运动占比44%（0-84%），非常剧烈运动占比34%（0-80%），运动强度的特征随时间推移保持稳定。参与者运动量（A）和运动强度（B）特征基线时有151人（52%）存在CAC，经随访增加到205人（71%）。CAC评分中位数由1（0-32）增加到31（0-132）。CAC评分≥100的比例由15%增加到31%，≥400的比例由6%增加到13%，≥1000的比例由1%增加到6%。冠状动脉粥样硬化斑块发生率由64%增加到83%，共有216人（75%）总斑块数量增加，150人（52%）钙化斑块增加，145人（50%）混合斑块增加，105人（36%）非钙化斑块增加。总的来说，无论是多变量校正模型，还是logistic回归分析，运动量与CAC和斑块进展没有关系。由于参与者的CAC评分要么保持在最低值，即0分，要么增加，因此，分析结果分为增加较少（消极增加）和增加较多（积极增加）。当将剧烈运动的占比作为连续变量时，与CAC的消极进展有关（每10%，β=-0.05，p=0.02），但是与斑块进展没有显著关联。非常剧烈运动的占比与CAC的积极进展有关（每10%，β=0.05，p=0.01）。非常剧烈运动与斑块的绝对数量增加无关，但与斑块进展有关，这可能是由钙化斑块增加导致的。敏感性分析支持了研究结果的稳健性。运动和运动强度与CAC评分进展和斑块数量变化的关系因此，总的来说，运动强度与冠状动脉粥样硬化的进展有关，其中剧烈运动与较少的CAC进展有关，而非常剧烈运动与更多的CAC和斑块进展有关，这可能主要是由于钙化斑块增加。未来，还需要更多研究评估这种在业余运动员中发现的运动强度与冠状动脉粥样硬化的关联，及对心血管疾病风险的影响，以确定这一现象的临床意义。参考文献： [1] Eijsvogels T M H, Molossi S, Lee D, et al. Exercise at the extremes: the amount of exercise to reduce cardiovascular events[J]. Journal of the American College of Cardiology, 2016, 67(3): 316-329. [2] Shiroma E J, Lee I M. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity[J]. Circulation, 2010, 122(7): 743-752. [3] Aengevaeren V L, Mosterd A, Braber T L, et al. Relationship between lifelong exercise volume and coronary atherosclerosis in athletes[J]. Circulation, 2017, 136(2): 138-148. [4] Aengevaeren V L, Mosterd A, Sharma S, et al. Exercise and coronary atherosclerosis: observations, explanations, relevance, and clinical management[J]. Circulation, 2020, 141(16): 1338-1350. [5] Merghani A, Maestrini V, Rosmini S, et al. Prevalence of subclinical coronary artery disease in masters endurance athletes with a low atherosclerotic risk profile[J]. Circulation, 2017, 136(2): 126-137. [6] DeFina L F, Radford N B, Barlow C E, et al. Association of all-cause and cardiovascular mortality with high levels of physical activity and concurrent coronary artery calcification[J]. JAMA cardiology, 2019, 4(2): 174-181. [7] Aengevaeren V L, Mosterd A, Bakker E A, et al. Exercise Volume Versus Intensity and the Progression of Coronary Atherosclerosis in Middle-Aged and Older Athletes: Findings From the MARC-2 Study[J]. Circulation, 2023.

2022-11-07

·BioSpace

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

Pre-screening study BASECAMP-1, is actively enrolling patients whose tumors have permanently lost HLA-A*02 AGOURA HILLS, Calif.--(BUSINESS WIRE)-- A2 Biotherapeutics , Inc., “A2 Bio”, is a biotechnology company focused on the development of first-in-class T cell therapeutics to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to selectively kill tumor cells while protecting normal cells. A2 Bio today announced four poster presentations showcasing: (1) BASECAMP-1, a master pre-screening trial to identify patients whose tumors have permanently lost HLA-A*02 (NCT04981119); (2) use of the Tempus xT Next Generation Sequencing (NGS) diagnostic to identify such patients; (3) data for A2 Bio’s lead program, A2B530, targeting CEA Cell Adhesion Molecule 5 (CEA); and (4) data for A2 Bio’s second program, A2B694, targeting mesothelin (MSLN). A2 Bio’s logic‑gated cell therapy utilizes dual receptors (an activator and blocker) and has demonstrated in vitro and in vivo the ability to kill tumor cells via the activator while protecting healthy cells via the blocker. Patients who may benefit from this therapy can be identified by using the Tempus diagnostic to pre-screen patients whose tumors have lost HLA-A*02. Once patients are identified, their T cells may be banked early in their disease course for potential utilization in a Phase 1 study in the event of relapse. “The unmet medical need in lung, colorectal and particularly pancreatic cancer remains extremely high. BASECAMP-1 is a non-interventional pre-screening trial that identifies eligible patients and banks their T cells. If the patients have the misfortune to relapse or progress, A2 Bio will have their cells ready to be manufactured and dosed in our upcoming Phase 1 studies targeting CEA and MSLN,” said William Go, MD, PhD, Chief Medical Officer of A2 Bio. Diane Simeone, MD, Director of the Pancreatic Cancer Center, Perlmutter Professor of Surgery at NYU and Principal Investigator on the study, stated, “BASECAMP-1 is an exciting trial that identifies patients with limited treatment options for a new and unique logic-gated CAR-T immunotherapy approach. We are thrilled to enroll patients at BASECAMP-1 and get them prepped for potential inclusion in Phase 1 studies in 2023.” The four poster presentations will be given on November 10, 2022 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting in Boston, MA. Details of the posters being presented on November 10, 2022 from 9am-9pm EST at the Poster Hall: Title: BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod CAR T-cell therapy Poster Number: 639 Presenter: Diane Simeone, MD, Director of the Pancreatic Cancer Center, Perlmutter Professor of Surgery at NYU and Chair of the Pancreatic Cancer Action Network’s (PanCAN) National Scientific and Medical Advisory Board Title: An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity Poster Number: 77 Presenter: Scott Kopetz, MD, PhD – Deputy Chair and Professor, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center Title: A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer Poster Number: 229 Presenter: J. Randolph Hecht, MD, Carol and Saul Rosenzweig Chair for Cancer Therapies Development, the Director of the UCLA Gastrointestinal Oncology Program and Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA Title: A2B694, an autologous logic-gated cell therapy targeting mesothelin Poster Number: 263 Presenter: Julian Molina, MD, PhD – Professor of Oncology and Consultant, Division of Medical Oncology at Mayo Clinic, Rochester ePosters will be released for viewing on November 10 at 7:00 am ET and can be viewed from the A2 Bio website ( ) About A2 Biotherapeutics A2 Biotherapeutics has invented the Tmod™ cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells. The Tmod™ mechanism utilizes two receptors to exploit common, specific gene losses in tumors that distinguish tumor from normal cells. A2 is positioned to deliver a broad pipeline of both autologous and allogeneic cell products, with in-house cGMP manufacturing, a leadership team with 90+ years combined experience in biotech and cell therapy, and a world-class scientific advisory board. A2 is backed by investors that include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents), Hartford HealthCare Endowment, StepStone Group, Schroders, Section 32 and Merck. For more information, please visit and linkedin.com/a2-biotherapeutics.

First in Class细胞疗法免疫疗法

100 项与 BCMab-1 相关的药物交易

登录后查看更多信息